Spectral sensing of ablation

• US 10,314,650 B2
• Filed: 12/29/2014
• Issued: 06/11/2019
• Est. Priority Date: 06/16/2010
• Status: Active Grant

• Current Assignee: Biosense Webster Israel Ltd. (Johnson & Johnson)
• Original Assignee: Biosense Webster Israel Ltd. (Johnson & Johnson)
• Inventors: Govari, Assaf, Beeckler, Christopher Thomas, Keyes, Joseph Thomas, Gliner, Vadim
• Primary Examiner(s): Fernandez, Katherine L
• Assistant Examiner(s): Kellogg, Michael S
• Application Number:
  US14/585,135
• Publication Number:
  US 20150119872A1
• Time in Patent Office: 1,625 Days
• Field of Search: None
• CPC Class Codes: A61B 18/1492 having a flexible, catheter-like structure, e.g. for heart ablation A61B18/1477 takes precedence
• CPC Class Codes: A61B 2017/00061 spectrum
• CPC Class Codes: A61B 2017/00066 intensity
• CPC Class Codes: A61B 2018/00357 Endocardium
• CPC Class Codes: A61B 2018/00577 Ablation
• CPC Class Codes: A61B 2018/00642 with feedback, i.e. closed loop control
• CPC Class Codes: A61B 2018/00738 Depth, e.g. depth of ablation
• CPC Class Codes: A61B 2018/1407 Loop
• CPC Class Codes: A61B 2218/002 Irrigation
• CPC Class Codes: A61B 2562/043 in a linear array
• CPC Class Codes: A61B 5/0075 by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy A61B5/0071 takes precedence
• CPC Class Codes: A61B 5/0084 for introduction into the body, e.g. by catheters A61B5/1459 takes precedence
• CPC Class Codes: A61B 5/0086 using infrared radiation
• CPC Class Codes: A61B 5/02007 Evaluating blood vessel condition, e.g. elasticity, compliance
• CPC Class Codes: A61B 5/4836 Diagnosis combined with treatment in closed-loop systems or methods A61B5/0036 takes precedence
• CPC Class Codes: A61B 5/6852 Catheters
• CPC Class Codes: A61B 5/6869 Heart

Abstract

A method for tissue assessment includes ablating tissue at a site within a body of a living subject using an invasive probe applied to the site. At a first stage in ablation of the tissue, first measurements are made of scattered light intensities from the site at a plurality of different wavelengths. At a second stage in the ablation of the tissue, subsequent to the first stage, second measurements are made of the scattered light intensities from the site at the plurality of different wavelengths. Progress of the ablation is assessed by computing different, respective measures of change in the scattered light intensities at the different wavelengths occurring between the first and second measurements, and comparing the respective measures.

Claims

1. A method for tissue assessment, comprising:

ablating the tissue at a site within a body of a living subject using an invasive probe applied to the site;

at a first stage in the ablation of the tissue, making first measurements of scattered light intensities from the site at a first wavelength, a second wavelength, and a third wavelength;

at a second stage in the ablation of the tissue, subsequent to the first stage, making second measurements of the scattered light intensities from the site at the first wavelength, the second wavelength, and the third wavelength;

computing a first ratio between the first measurement and the second measurement at the first wavelength, computing a second ratio between the first measurement and the second measurement at the second wavelength, and computing a third ratio between the first measurement and the second measurement at the third wavelength;

dividing a product of the second and third ratios by the first ratio to determine an overall ratio value;

estimating a size of a lesion based on the overall ratio value; and

controlling the ablation of the tissue based on the estimated size of the lesion.

2. The method according to claim 1, wherein ablating the tissue comprises ablating a myocardial tissue in a heart of the subject.

3. The method according to claim 1, wherein ablating the tissue comprises inserting a catheter into the body and applying energy to the tissue via the catheter.

4. The method according to claim 1, wherein making the first and second measurements comprises directing light toward the site from an emitter in the probe, and collecting the light scattered from the tissue using a receiver in the probe.

5. The method according to claim 4, wherein the probe includes a cap having an optical port disposed at a distal end of the probe, and the emitter and the receiver comprise at least one optical fiber, which extends through the probe and terminates at the optical port.

6. The method according to claim 1, wherein the first wavelength is in a visible light range and the second wavelength is in an infrared light range.

7. The method according to claim 6, wherein the first wavelength is between 600 and 700 nm, and the second wavelength is between 700 and 800 nm.

8. The method according to claim 7, wherein the first wavelength is between 630 and 670 nm, the second wavelength is between 750 and 790 nm, and the third wavelength is between 670 and 710 nm.

9. The method according to claim 1, wherein said controlling includes automatically controlling the ablation of the tissue.

10. The method according to claim 1, wherein the first intensity measurement comprises a first peak and the second intensity measurement comprises a second peak.

11. A medical apparatus, comprising:

an invasive probe having a distal end, the invasive probe including a cap having an optical port disposed at the distal end, and an optical fiber extending through the probe and terminating at the optical port, the invasive probe being configured to ablate a tissue at a site within a body of a living subject;

a radiation source connected to the optical fiber;

a detector connected to the optical fiber; and

a processor connected to the radiation source and the detector,

wherein the processor is configured to;

receive a first intensity measurement and a second intensity measurement from the detector;

compute a first ratio between the first intensity measurement and the second intensity measurement at a first wavelength, a second ratio between the first intensity measurement and the second intensity measurement at a second wavelength, and a third ratio between the first intensity measurement and the second intensity measurement at a third wavelength;

divide a product of the second and third ratios by the first ratio to determine an overall ratio value;

estimate a size of a lesion based on the overall ratio value; and

control the ablation of the tissue based on the estimated size of the lesion.

12. The apparatus according to claim 11, wherein the probe comprises a catheter, which is configured to ablate a myocardial tissue in a heart of the subject.

13. The apparatus according to claim 11, wherein the first intensity measurement comprises a first peak and the second intensity measurement comprises a second peak.

14. The apparatus according to claim 11, wherein the first wavelength is in a visible light range and the second wavelength is in an infrared light range.

15. The apparatus according to claim 14, wherein the first wavelength is between 600 and 700 nm, and the second wavelength is between 700 and 800 nm.

16. The apparatus according to claim 15, wherein the first wavelength is between 630 and 670 nm, the second wavelength is between 750 and 790 nm, and the third wavelength is between 670 and 710 nm.

17. The apparatus according to claim 11, wherein the processor is further configured to control the ablation of the tissue automatically.